Objective: Despite multiple landmark clinical trials, little data exists on real-world cost of carotid artery stenting (CAS) and carotid endarterectomy (CEA) to the United States healthcare system. We aim to study differences in actual hospitalization cost between patients who underwent CAS vs CEA in a nationally representative database.
The prevalence of carotid artery stenosis in the United States range from 7% to 9% by the eighth decade of life. 1 Carotid endarterectomy (CEA) is considered the standard of care for asymptomatic patients with >70% stenosis and symptomatic patients with >50% stenosis of the carotid artery, whereas carotid artery stenting (CAS) is, generally, reserved for patients at a high risk for CEA. 2 Recent clinical trials reported noninferiority in long-term clinical outcomes of the less invasive CAS procedure compared with CEA. [3] [4] [5] [6] However, short-term perioperative stroke and death rates are still more favorable following CEA. 6 In lieu of these findings, and the increasing utilization of CAS, [7] [8] [9] other factors including the cost of these two procedures, would have greater influence on decision making. In 2010, a study describing the cost of hospitalization found a $3500 higher cost per quality-adjusted life year for CAS compared with CEA. 9 In addition, since
2003, several studies have demonstrated higher hospitalization costs for patients undergoing CAS compared with CEA. [10] [11] [12] [13] In particular, Sternbergh et al 14 concluded
that patients managed by CAS incurred 40% higher cost without significant improvement in clinical outcomes or reduction in length of stay (LOS). However, those single-center studies reported wide variations in the cost of hospitalization.
On the national scale, however, the limited number of reports do not take into account differences in cost between revascularization methods and patient symptomatology. 9, 17, 18 Hence, in this study we sought to assess differences in hospitalization cost between CAS and CEA among asymptomatic and symptomatic patients in an all-payers nationally representative dataset in the United States.
METHODS
We studied hospital discharge and billing records of patients, in the Premier Perspective Database, who underwent CEA or CAS between years 2009 and 2015. The database used is a voluntary, fee-supported collection of retrospective data that is maintained by Premier, Inc (Charlotte, NC), to assess healthcare quality and resource utilization. As deidentified patient information was used in this manuscript, patient consent was waived; the study was approved by the Johns Hopkins Institutional Review Board.
The Premier Perspective Database contains detailed demographic information and an extended list of billing files relating to each patient, procedure, and hospital. Details pertaining to patient medication were abstracted from billing files. Cost data were collected from patient discharge (discharge total charges, total cost, total variable cost, and total fixed cost) and billing files (billing charges, cost, variable cost, and fixed cost). Premier, Inc reconciles patient billing to the discharge record within 1% variance and reconciles the discharge data to the financial statement within 2% variance. If the variance is out of range, Premier, Inc works with the hospital to correct any potential errors. Premier, Inc. captures actual cost and charge data from hospital members that have a cost accounting system or in the instance where a hospital member does not have a system to estimate cost, Premier, Inc uses a departmentspecific Medicare cost-to-charge ratio to determine the cost. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to identify patients undergoing a CEA or CAS (ICD-9-CM codes, 38.12 and 00.63, respectively). Patients were classified as being symptomatic if they had a history of transient ischemic attack, a history of transient retinal artery occlusion, or were admitted for carotid artery occlusion with stroke. Patients were classified as asymptomatic if they were admitted for carotid artery occlusion without stroke, or precerebral artery occlusion without stroke. Patient comorbidity was determined using a set of ICD-9-CM codes as illustrated in the Supplementary Table (online only). Patient race was classified using Premier, Inc categories for race. Specifically, patients were categorized as White, Black, Hispanic, or other (American Indian, Asian/Pacific Islander, or "not specified"). Insurance status was classified into four categories: Medicare, Medicaid, private, and other. The "other" insurance category represents charity, worker's compensation, direct employer contract, other government payers, indigent, and other type of payments. Premier, Inc recorded admission type (elective/urgent/ emergent) using the uniform billing (UB-04) codes. The primary outcome of interest was total in-hospital patient cost, including fixed (administrative, capital, and utilities) and variable costs (labor and supply). Cost data were presented as medians, inflation-adjusted for 2015 dollars and rounded to nearest dollar. Patients who had any concomitant endovascular (stenting of arteries other than the carotids) or open major surgery (coronary artery bypass grafting or other bypass surgeries) during the same index hospital visit were excluded from the analysis.
Categorical data were reported as whole numbers and proportions, whereas continuous data were reported as means with standard deviation (SD), or medians, as appropriate. Pearson c 2 test was used to compare categorical data whereas Student t-test was used to compare mean patient age and nonparametric K-sample equality-of-medians test to compare cost and LOS data. To ensure the homogeneity of our patient cohort, patients who underwent CAS were matched with those who underwent CEA using propensity scores. The use of propensity score matching decreases the risk for selection bias and adjusts for potential confounders between the two treatment groups. Specifically, patients were matched using a nearest-neighbor 1:1 matching algorithm with a caliper width of 0.001 SDs of the estimated log-odds of receiving one procedure vs the other. Two independent models were generated for symptomatic and asymptomatic patients, each of which adjusted for all available patient, hospital, and provider level characteristics (a total of 32 variables). All statistical analysis was performed using Stata 14.1 statistical software (StataCorp, College Station, Tex). A P value of <.05 was considered statistically significant. 
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RESULTS
Across the study period, a total of 115,548 (9.3% asymptomatic, 9.7% symptomatic) patients were identified. The mean age was 71 and 69 years; 58% and 57% were male patients; and 81% and 77% were white among asymptomatic and symptomatic patients, respectively. Patients who underwent CAS were more likely to present with congestive heart failure (CHF) and peripheral artery disease compared with CEA regardless of symptomatic status. Among asymptomatic patients (90.3%, n ¼ 104,394), those who underwent CAS were less likely to be admitted electively (75.5% vs 85.2%; P < .001), and to receive beta blockers (52.8% vs 70%; P < .001), or other antihypertensive medications (26.1% vs 41.5%; P < .001). Asymptomatic patients who underwent CAS were more likely to receive clopidogrel (90.1% vs 33.2%; P < .001) compared with patients who underwent CEA. Among symptomatic patients (9.7%, n ¼ 11,154), those who underwent CAS were 1.3 years younger on average [mean (SD): 68.3 (11.6) vs 69.6 (10.4); P < .001], and were more likely to present with a history of transient ischemic attack (30.1% vs 25.7%; P < .001), receive clopidogrel (91.5% vs 42.9%; P < .001), and get admitted to an urban hospital (95.7% vs 86.8%; P < .001) compared to patients who underwent CEA (Table I) .
After propensity score matching, 25,812 (12,906 CEA and CAS) asymptomatic and 3864 (1932 CEA and CAS) symptomatic patients were included in the analysis. There was no difference in patient demographic and comorbidity as well as hospital characteristics between patients who underwent CAS compared with CEA, except for the proportion of aspirin/other antiplatelets and statin users (all differences <3%, Table II ). The total hospitalization cost for patients who underwent CAS was 40% ($11,814 vs $8378; P < .001) and 37% ($19,426 vs $14,190; P < .001) higher compared with patients who underwent CEA among asymptomatic and symptomatic patients, respectively. The total fixed and variable cost for patients who underwent CAS was 7.8% ($4065 vs $4384; P < .001) and 77.7% ($4152 vs $7377; P < .001) higher among asymptomatic patients and 15.5% ($6770 vs $7819; P < .001) and 61.5% ($6874 vs $11,099; P < .001) higher among symptomatic patients compared with patients who underwent CEA, respectively. Furthermore, the hospitalization cost for patients who underwent CAS was significantly higher than CEA among all U.S. census regions. For example, in the Northeast region, patients who underwent CAS incurred 64.8% ($8860 vs $14,602; P < .001) and 50% ($18,341 vs $7492; P < .001) higher total hospitalization cost compared with patients who underwent CEA among asymptomatic and symptomatic patients, respectively (Table III) . The median LOS for patients who underwent CAS was similar to that for patients who underwent CEA among asymptomatic (1 day) and symptomatic (5 days) patients. After stratifying by symptomatic status and surgeon specialty, patients who underwent CAS incurred higher total hospitalization cost compared with patients who underwent CEA (Fig) . Specifically, asymptomatic patients who underwent CAS performed by any surgical specialty incurred an average of $2717 to $4918 higher total hospitalization cost compared with patients who underwent CEA (all P < .001). Among symptomatic patients, those who underwent CAS performed by vascular, cardiac, and neurologic surgeons, incurred $2108 ($16,114 vs $14,006; P ¼ .006), $7055 ($17,351 vs $10,296; P ¼ .023) and $6479 ($27,290 vs $20,811; P ¼ .002) higher total hospitalization cost compared with patients who underwent CEA, respectively (Table III) . Vascular surgeon performed most CEA procedures for asymptomatic (53.0%) and symptomatic (52.5%) patients, while cardiologist performed most CAS procedures for asymptomatic patients (36.0%) and intervention radiologists performed most CAS procedures for symptomatic patients (22.8%) (Table IV) .
DISCUSSION
We have shown in more than 100,000 cases performed in the United States that the average age of any patient receiving carotid revascularization was 71 years. However, the propensity score models showed that symptomatic patients received interventions 1-2 years earlier than their asymptomatic counterparts. This is in line with the Society for Vascular Surgery guidelines, (Continued on next page) which recommend earlier intervention for symptomatic patients. 2 In addition, asymptomatic patients have a higher proportion of White race (83%) and less proportion of African Americans (4%) compared with symptomatic patients (78% and 6%, respectively) ( Table I ). This racial disparity may reflect an underlying difference in socioeconomic factors, which have been shown to be associated with delayed access to healthcare. [19] [20] [21] Baseline comorbidities in patients who underwent carotid revascularization showed some distinctions between patients who underwent CEA vs CAS. The majority of patients understudy were hypertensive. Apart from hypertension, symptomatic patients who underwent CAS were generally sicker. The higher comorbidity profile among patients who underwent CAS was reported previously in other population-based nonrandomized studies. 22, 23 The differential referral of patients with high comorbidities, such as history of unstable angina, severe CHF or chronic obstructive pulmonary disease, to undergo CAS instead of CEA might explain this difference. 24 In our cohort, patients who underwent CAS were more likely to present with CHF compared with patients who underwent CEA among asymptomatic (14.4% vs 8.1%; P < .001) and symptomatic (11.9% vs 6.8%; P < .001) patients. Other variations in baseline comorbidities included peripheral arterial disease, which was proportionally more prevalent among patients who underwent CAS compared with CEA in both symptomatic (20.9% vs17.4%; P < .001) and asymptomatic (18.8% vs 13.4%; P < .001) groups. The use of aspirin, clopidogrel, and statins was higher among asymptomatic patients who underwent CAS. This might be explained by the higher prevalence of comorbid conditions among asymptomatic patients who underwent CAS in our cohort and by the common practice of administering perioperative dual antiplatelet therapy for those patients.
Our study presents an analysis of actual total inpatient costs incurred by a large, nationally representative sample of patients in the U.S. healthcare system. Prior studies using the Nationwide Inpatient Sample have used hospital charge data to compare costs of carotid revascularization. 9, 17, 18 Because of geographic variations and differences between payer systems, charge data tends to significantly overestimate actual costs incurred by patients. 25 Our findings, based on actual hospital cost in 73% of patients and cost generated by department-specific Medicare cost-to-charge ratio in 27% of patients, demonstrated that patients who underwent CAS incurred 40% and 37% higher total hospitalization cost compared with patients who underwent CEA after matching on age, sex, comorbidities, medications use, and hospital characteristics, among asymptomatic and symptomatic patients, respectively. Prior studies reported an additional cost associated with CAS, ranging from 40% to 54%. 13, 14 Patients who underwent CAS stayed in hospital for a similar time period compared with patients who underwent CEA, hence, it is less likely that LOS would influence the additional cost associated with CAS procedures. Total variable costs incurred by patients who underwent CAS, which include supply and labor, were on average 77.7% and 61.5% higher than CEA, among asymptomatic and symptomatic patients, respectively. This is perhaps explained by cost of stent(s), embolic protection devices, balloons, catheters, and wires used to perform CAS procedures. 26 The total fixed cost associated with CAS procedures, which include administrative fees, capital, and utilities, was not as prominently different from that associated with CEA procedures. The difference in the total fixed cost associated with CAS was $319 to $1049 higher than the total fixed cost associated with CEA, among asymptomatic and symptomatic patients, respectively. These differences in total fixed cost between the two procedures could be accounted for by differences in the usage of additional intraoperative time, and resources, such as interventional/hybrid operating rooms and additional cost of fluoroscopy or the use of different neurologic monitoring modalities depending on physician specialty.
26,27
The current study reported a high proportion of patients managed at hospitals in the South region. The reason behind this regional variation is multiple. First, we expected a high proportion of patients in the South because the resident population of the South is the highest in the United States, about 37%. 28 Second, the proportion of patient in the entire Premier Perspective Database is highest in the south as well, about 45% (13% in the Northeast, 23% in the Midwest, and 19% in the West). Our findings, however, indicates that patients in the South region were more likely to undergo a carotid revascularization procedure than in another region. We reported that more than one-half of patients (54.4%) were treated in the South. However, to accurately compare the incidence of carotid revascularization procedures between regions in the United States, a calculation of a population-standardized rate must be performed. Of note, the current study identified higher cost of hospitalization incurred by patients who were managed at hospitals in the Northeast region and by neurologic surgeons (Table III) . However, further studies adjusting for patients variabilities among different regions and specialty is needed to accurately identify reasons for variation in the cost of hospitalization. The Premier Perspective Database was chosen for the current analysis because of its large population size, and detailed and reliable cost-related data. 29 The lack of certain information pertaining to patient enrollment in clinical trials or registries for CAS or CEA procedures, could have biased our outcomes because those patients tend to incur lower costs than their nonenrolled counterparts. 14 In addition, as with any large database, there is a risk of systematic biases or incomplete data. However, we do not expect this to affect our analysis, as cost data in our cohort was not missing in any observation. It should be noted that the findings of this study were limited to the in-hospital period. Future studies in a patient cohort with longer follow-up time while factoring in the costs of postoperative complications is needed to further understand the difference in the overall financial burden of the two procedures on the U.S. healthcare system.
CONCLUSIONS
The total hospitalization cost incurred by patients who underwent CAS was significantly higher than for those who underwent CEA, despite matching patients based on all potential confounders and stratifying by symptomatic status, type of cost, hospital region, and surgeon specialty. There was a marked variability in the incremental cost of hospitalization associated with CAS procedures between census regions and surgeon specialties. Our findings provide additional important information giving the ongoing controversy regarding the appropriate indication for CAS. 
AUTHOR CONTRIBUTIONS
